ADMA Biologics faces renewed securities litigation pressure as DJS Law Group reactivates investor outreach for August 2026 class action
Executive summary: The DJS Law Group issued a press release on August 5, 2026, re-released August 6, 2026, reminding investors of an existing class action lawsuit against ADMA Biologics for alleged securities law violations under Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. The renewed outreach signals active plaintiff solicitation ahead of the August 10, 2026 lead plaintiff deadline, increasing litigation risk and potential financial exposure for ADMA, while highlighting persistent investor concerns about past disclosures.
Who is involved: ADMA Biologics, Inc. (NASDAQ: ADMA), the DJS Law Group (plaintiff outreach firm), and investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 (the putative class period).
Likely next: Investors may seek lead plaintiff status before the August 10, 2026 deadline; if appointed, discovery proceedings will likely intensify, potentially leading to settlements or trial preparations later in Q3 or Q4 2026.
ADMA Biologics, Inc. is once again the subject of a class action lawsuit reminder issued by the DJS Law Group, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The notice, dated August 5, 2026 and reissued August 6, 2026, targets investors who purchased ADMA securities between August 9, 2024 and March 25, 2026. This follows a pattern of repeated legal reminders from multiple law firms concerning the same alleged misrepresentations regarding ADMA’s financial condition and revenue recognition. The recurrence suggests ongoing investor concern and potential coordination among plaintiff firms ahead of the August 10, 2026 lead plaintiff deadline.
Timeline
- — ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA (PR Newswire)
- — Robbins LLP Reminds ADMA Investors of the August 10, 2026 Lead Plaintiff Deadline; Contact the Firm for Information About Recovering Your Losses (PR Newswire)
Analysis — what this means
Likely next events
- August 10, 2026: Deadline for investors to seek lead plaintiff status in the ADMA class action (per Robbins LLP notice, Aug 5, 2026)
- August 13, 2026: Expected publication of ADMA’s Q2 2026 financial results (implied from prior filing patterns and ATRenew analogy)
- September 2026: Potential commencement of discovery if lead plaintiff is appointed by mid-August
- October 2026: Possible mediation or settlement discussions, typical timing for securities class actions post-discovery initiation
Sectors affected
- Biologics and specialty pharmaceuticals
- Plasma-derived therapeutics
- Investor litigation services
Regulatory implications
- Potential for increased disclosure controls review under SOX Section 404 if internal controls over revenue recognition are questioned
- Ongoing litigation may trigger NASDAQ listing compliance review if governance or reporting deficiencies are found
Historical parallels
- ADMA’s 29% stock drop on August 4, 2026 following Culper Research channel stuffing allegations (similar to Valeant Pharmaceuticals 2015)
- Repeated DJS Law Group outreach mirrors pattern seen in Securities Exchange Commission v. Tesla (2018) investor litigation waves
- August 10, 2026 lead plaintiff deadline parallels tactics in In re: Facebook Securities Litigation (2018) deadline-driven solicitation
Key entities
Sources
Open the full interactive case file on Beyond →